Abstract:Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. Methods GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide. The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are described here. Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1. In group A, all patients received atezolizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks. In group F, patients were randomly assigned (1:1) to receive intravenous atezolizumab (1200 mg) plus intravenous bevacizumab (15 mg/kg) every 3 weeks or atezolizumab alone by interactive voice-web response system using permuted block randomisation (block size of two) and stratification factors of geographical region; macrovascular invasion, extrahepatic spread, or both; and baseline a-fetoprotein concentration. Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-totreat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1. In both groups, safety was assessed in all patients who received at least one dose of any study treatment. This study is registered with ClinicalTrials.gov, NCT02715531, and is closed to enrolment. Findings In group A, 104 patients were enrolled between July 20,2016, and July 31,2018, and received atezolizumab plus bevacizumab. With a median follow-up of 12.4 months (IQR 8.0-16.2), 37 (36%; 95% CI 26-46) of 104 patients had a confirmed objective response. The most common grade 3-4 treatment-related adverse events were hypertension (13 [13%]) and proteinuria (seven [7%]). Treatment-related serious adverse events occurred in 25 (24%) patients and treatment-related deaths in three (3%) patients (abnormal hepatic function, hepatic cirrhosis, and pneumonitis). In group F, 119 patients were enrolled and randomly assigned (60 to atezolizumab plus bevacizumab; 59 to atezolizumab monotherapy) between May 18,2018, and March 7,2019. With a median follow-up of 6.6 months (IQR 5.5-8.5) for the atezolizumab plus bevacizumab group and 6.7 months (4.2-8.2) for the atezolizumab monotherapy group, median progression-free survival was 5.6 months (95% CI 3.6-7.4) versus 3.4 months (1.9-5.2; hazard ratio 0.55; 80% CI 0.40-0.74; p=0.011). The most common grade 3-4 treatment-related adverse events in group F were hypertension (in three [5%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group) and proteinuria (in two [3%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group). Treatment-related serious adverse events occurred in seven (12%) patients in the atezolizumab plus bevacizumab group and two (3%) patients in the atezolizumab monotherapy group. There were no treatment-related deaths. Interpretation Our study shows longer progression-free survival with a combination of atezolizumab plus bevacizumab than with atezolizumab alone in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy. Therefore, atezolizumab plus bevacizumab might become a promising treatment option for these patients. This combination is being compared with standard-of-care sorafenib in a phase 3 trial. Copyright (C) 2020 Elsevier Ltd. All rights reserved.

MO19390 (sail): Incidence of Hemorrhage with First-Line Bevacizumab (Bv)-Based Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

MO19390 (sail): Incidence and Management of Hypertension (HTN) During Bevacizumab (Bv)-Based First-Line Therapy in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).

P2.01-030 Real World Study of Bevacizumab-Contained Regimen As First Line Therapy in Chinese Patients with Advanced NSCLC

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): an Open-Label, Multicentre, Phase 1b Study

The Optimal Timing And Courses Of Bevacizumab Added To Chemotherapy For Non-Squamous Non-Small Cell Lung Cancer: Revelations From The Real-World Experience In A Single Chinese Cancer Center

Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.

A Prospective, Multicenter, Observational Study of Bevacizumab in Combined with Chemotherapy As First-Line or Second-Line Treatment in Chinese Metastatic Colorectal Cancer

Results of ML18147: A Phase III Study of Bevacizumab in Second-Line MCRC for Patients Pretreated with Bevacizumab in First Line

Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first‐line chemotherapy: A multicenter prospective cohort study

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Efficacy and Safety of IBI305 Compared with Bevacizumab in Advanced Non-Squamous NSCLC Patients As First-Line Treatment in a Randomized, Double-Blind, Phase III Study.

Efficacy and Safety of MIL60 Compared with Bevacizumab in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer: a Phase 3 Randomized, Double-Blind Study

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

A Prospective Multicenter Observational Study of Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Chinese Patients (obtain Study).

Comparison of the Effects of Bevacizumab (bv) in Combination with Chemotherapy (ct) and Ct Alone on the Incidence of Brain Metastases (bm) in Non-Small Cell Lung Cancer (nsclc): A Retrospective Clinical Analysis

Bevacizumab (Bev) And Risk Of Hemorrhage (Hem) In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Treated On Calgb 90401 (Alliance).

P2.01-029 Real World Report of Clinical Outcomes of Bevacizumab in First-Line or Later-Line Treatment for Patients with Advanced NSCLC